Skip to main content
. 2014 Aug;14(16):1923–1938. doi: 10.2174/1568026614666140929124445

Fig. (2).

Fig. (2)

Workflow for the discovery of mutant-specific PI3Kα inhibitors based on a SBVS protocol involving conformer generation, binding site prediction, and compound post-processing.